Adapting low-dose buprenorphine induction to meet patient needs: A pilot study

Area of Science:

• Addiction Medicine
• Pharmacology
• Clinical Research

Background:

• Low-dose buprenorphine induction (LDBI) is a strategy to initiate buprenorphine treatment in patients on full opioid agonists.
• This method aims to mitigate the risk of precipitated withdrawal during the transition to buprenorphine therapy.

Purpose of the Study:

• To evaluate the real-world effectiveness of LDBI protocols.
• To determine how patient-specific adjustments influence success rates in buprenorphine conversion.

Main Methods:

• A case series design was employed, analyzing patients treated by the Addiction Medicine Consult Service.
• The study included patients initiated on LDBI using a transdermal buprenorphine patch followed by sublingual buprenorphine-naloxone.
• Data collected included morphine milligram equivalents (MME) prior to and during induction, induction duration, and final maintenance dose.

Main Results:

• Out of 21 patients, 19 (91%) successfully completed LDBI and converted to a maintenance buprenorphine dose.
• Patients who successfully converted had a median of 113 MME (IQR 63-166) in the 24 hours prior to induction.
• Patients who did not convert had a median of 83 MME (IQR 75-92) in the 24 hours prior to induction.

Conclusions:

• The combination of transdermal buprenorphine followed by sublingual buprenorphine-naloxone demonstrated a high success rate for LDBI.
• Individualized adjustments to LDBI protocols may be beneficial for achieving successful buprenorphine conversion.